

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A monoclonal antibody or fragment thereof which is reactive with HIV-1 neutralizing antibody 2F5 produced by a hybridoma cell line having the (ECACC Accession No. 90091704) and which inhibits or prevents either or both of the HIV-1 neutralization activity of antibody 2F5 or the binding of antibody 2F5 to gp41 of HIV-1, the fragment being an antigen-binding part of the antibody which retains the binding specificity of the whole antibody, wherein the antibody is anti-idiotypic to antibody 2F5 and ~~has all characteristics of an antibody~~ is produced by hybridoma cell line 3H6 having the (ECACC Acc. No. 01100279).
2. (Previously presented) The antibody or fragment thereof according to claim 1, wherein it inhibits or prevents binding of antibody 2F5 to proteins or peptides that comprise an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO 12.
3. (Previously presented) The antibody or fragment thereof according to claim 1, wherein it elicits upon administration to a mammal Ab3-type antibodies that have either or both of an HIV-1 neutralizing activity, or an ability to compete with antibody 2F5 for binding to proteins or

peptides that comprise an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO 12.

4-5. (Canceled.)

6. (Previously presented) The antibody or fragment thereof according to claim 1, wherein the antibody has either or both of a heavy chain variable region according to SEQ ID NO 14 or light chain variable region according to SEQ ID NO 15.

7. (Previously presented) The antibody or fragment thereof according to claim 1, wherein the antibody is a chimeric mouse/human antibody or a humanized version of a mouse antibody.

8. (Previously presented) The antibody or fragment thereof according to claim 1, wherein it is linked to an immunoactive molecule that increases or intensifies a B cell response.

9. (Previously presented) The antibody or fragment thereof according to claim 1, for use as a screening tool or a diagnostic or therapeutic agent.

10. (Previously presented) A hybridoma cell line producing an antibody according to claim 1, the cell line being 3H6 deposited at PHLS, Porton Down, Salisbury, UK, under ECACC Acc. No. 01100279.

11-12. (Canceled.)

13. (Previously presented) A pharmaceutical composition or vaccine, comprising an antibody or antibody fragment defined in claim 1, and a pharmaceutically acceptable carrier.

14-18. (Canceled.)

19. (Previously presented) The antibody or fragment thereof according to claim 8, wherein the immunoactive molecule is a cytokine selected from the group consisting of interleukin-4 (IL-4) and interleukin-15 (IL-15).